COVID-19 Vaccine (inactivated, adjuvanted) Valneva


COVID-19 vaccine (inactivated, adjuvanted, adsorbed)

This medicine is authorised for use in the European Union.


COVID-19 Vaccine (inactivated, adjuvanted) Valneva is a vaccine for protecting people aged between 18 and 50 years against coronavirus disease 2019 (COVID-19). It is used for primary vaccination.

The vaccine contains whole particles of the original strain of SARS-CoV-2 (the virus that causes COVID-19) that has been inactivated (killed) and cannot cause the disease.

This EPAR was last updated on 04/04/2023

Authorisation details

Product details
COVID-19 Vaccine (inactivated, adjuvanted) Valneva
Agency product number
Active substance
SARS-CoV-2 virus (inactivated) Wuhan strain hCoV-19 / Italy / INMI1-isl / 2020
International non-proprietary name (INN) or common name
COVID-19 vaccine (inactivated, adjuvanted, adsorbed)
Therapeutic area (MeSH)
COVID-19 virus infection
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Valneva Austria GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Campus Vienna Biocenter 6
A-1030 Vienna

Product information

24/03/2023 COVID-19 Vaccine (inactivated, adjuvanted) Valneva - EMEA/H/C/006019 - II/0004

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

COVID-19 Vaccine (inactivated, adjuvanted) Valneva is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 to 50 years of age. 

The use of this vaccine should be in accordance with official recommendations.

Assessment history

Safety updates

Related content

How useful was this page?

Add your rating
10 ratings
4 ratings
2 ratings
1 rating